Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||The neuroimmunology of chronic pain: from rodents to humans|
|Citation:||The Journal of Neuroscience, 2021; 41(5):855-865|
|Publisher:||Society for Neuroscience|
|Peter M. Grace, Vivianne L. Tawfik, Camilla I. Svensson, Michael D. Burton, Marco L. Loggia and Mark R. Hutchinson|
|Abstract:||Chronic pain, encompassing conditions, such as low back pain, arthritis, persistent post-surgical pain, fibromyalgia, and neuropathic pain disorders, is highly prevalent but remains poorly treated. The vast majority of therapeutics are directed solely at neurons, despite the fact that signaling between immune cells, glia, and neurons is now recognized as indispensable for the initiation and maintenance of chronic pain. This review highlights recent advances in understanding fundamental neuroimmune signaling mechanisms and novel therapeutic targets in rodent models of chronic pain. We further discuss new technological developments to study, diagnose, and quantify neuroimmune contributions to chronic pain in patient populations.|
|Keywords:||Sex differences; TSPO; Nrf2; biomarkers; Fc gamma receptors; cannabinoids|
|Rights:||© 2021 the authors. Authors grant JNeurosci a license to publish their work and copyright remains with the author. For articles published after 2014, the Society for Neuroscience (SfN) retains an exclusive license to publish the article for 6 months; after 6 months, the work becomes available to the public to copy, distribute, or display under the terms of the Creative Commons Attribution 4.0 International License (CC-BY). This license allows data and text mining, use of figures in presentations, and posting the article online, provided that the original article is credited.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.